盘点:二甲双胍,能否成为“抗癌卫士”?

2016-09-21 Mechront MedSci原创

二甲双胍是治疗糖尿病的“明星”药物;但二甲双胍的“野心”还不止于此,它能成为新一代的“抗癌卫士”吗? 【1】二甲双胍还可以治疗胰腺癌? 研究纳入了1916名PDAC患者,在诊断腺癌前存在DM,且使用降糖药1年以上。其中1098例(57.3%)使用二甲双胍治疗,818例(42.7%)使用其他降糖药治疗。 二甲双胍与非二甲双胍组相比,平均生存分别为5.5个月和4.2个月(P<

二甲双胍是治疗糖尿病的“明星”药物;但二甲双胍的“野心”还不止于此,它能成为新一代的“抗癌卫士”吗?

【1】二甲双胍还可以治疗胰腺癌


研究纳入了1916名PDAC患者,在诊断腺癌前存在DM,且使用降糖药1年以上。其中1098例(57.3%)使用二甲双胍治疗,818例(42.7%)使用其他降糖药治疗。

二甲双胍与非二甲双胍组相比,平均生存分别为5.5个月和4.2个月(P<0.01)。校正包括DCSI评分、Charlson评分、慢性肾脏疾病(CKD)等混杂因素后,二甲双胍组的患者与其他患者相比,死亡风险下降12%(HR=0.88, 95%CI: 0.81-0.96, P<0.01)。分层分析显示,不管DCSI评分、Charlson评分、CKD或是否使用胰岛素/其他降糖药物,以上差异仍存在(所有P<0.01)。

使用二甲双胍治疗的糖尿病患者,相比其他降糖药治疗的患者而言,诊断PDAC后其生存有改善。这些结果提示二甲双胍或许可以作为糖尿病+PDAC患者的辅助治疗。(文章详见——Am J Gastroenterol:二甲双胍还可以治疗胰腺癌?

【2】糖尿病药物二甲双胍或可有效预防并治疗乳腺癌

研究人员首先检测了二甲双胍的治疗对乳腺癌患者生存率的影响,研究者对在1997年至2013年间诊断为乳腺癌或者进行手术疗法的1215名患者进行了相应的临床试验并且检测了患者的临床治疗效果,其中97名患者在诊断前利用二甲双胍进行治疗,而另外97名患者在诊断后利用二甲双胍进行治疗。

结果表明,相比不服用二甲双胍的患者而言,在乳腺癌诊断前摄入二甲双胍的患者死亡的可能性是前者的2倍,而当患者诊断为乳腺癌后使用二甲双胍进行治疗,则死亡的可能性大约是不服用二甲双胍患者50%。医学博士Yun Rose Li说道,利用二甲双胍作为癌症预防措施目前仍然存在争议,而且很多研究结果并不一致,我们在研究中发现,二甲双胍和使用时间存在明显关联,这或许就可以解释很多研究所得结果不一致的问题了。研究人员发现,使用二甲双胍可以明显改善某些乳腺癌患者的存活率。(文章详见——ASCO 2016 :糖尿病药物二甲双胍或可有效预防并治疗乳腺癌)

【3】2型糖尿病人群使用二甲双胍可显著降低肾癌风险


该研究纳入了≥40岁的171753名现在使用或既往使用过二甲双胍的患者,还有75499名服用其他降糖药物的患者,对参与者随访6个月。

研究结果显示,随访期间二甲双胍使用组和对照组分别出现了917例和824例肾癌,各自的发生率分别为80.09/100,000人年和90.30/100,000人年。二甲双胍使用患者与对照组相比,可显著降低肾癌风险(HR=0.279,0.254-0.307);根据二甲双胍使用时间分为<14.5个月、14.5-45.8个月、>45.8个月分为三组,与没有使用二甲双胍的患者相比,肾癌风险分别为HR=0.598 (0.535-0.668)、0.279 (0.243-0.321)、0.104 (0.088-0.124)。亚组分析显示,不管男女,不管有没有联合其他降糖药物,使用二甲双胍均可降低肾癌风险。

研究结果表明,2型糖尿病人群使用二甲双胍可显著降低肾癌风险。(文章详见——Eur J Cancer:2型糖尿病人群使用二甲双胍可显著降低肾癌风险

【4】神药二甲双胍可以降低甲状腺癌风险吗?

研究者使用英国的临床实践研究数据链(CPRD)进行了一项病例对照研究(1995~2014年)。纳入了第一次诊断为甲状腺癌的患者,每例患者根据年龄、性别等匹配六名对照组。校正BMI、吸烟、糖尿病后,估计两者间OR和95%CI。

该研究共纳入了1229例甲状腺癌以及7374例对照组。研究数据显示,曾使用过二甲双胍治疗的患者其甲状腺癌风险aOR=1.48, 95 % CI 0.86-2.54。长期使用(≥30张处方)二甲双胍治疗的患者其甲状腺癌风险aOR=1.83, 95 % CI 0.92-3.65,但该病例很少仅仅只有26例。使用磺脲类、胰岛素、噻唑烷二酮类(TZD)治疗的患者没有发现上述联系。新诊断糖尿病对甲状腺癌风险aOR=1.17, 95 % CI 0.89-1.54,糖尿病病程>8年对甲状腺癌风险aOR=1.22, 95 % CI 0.60-2.51。

研究结果表明,不管是二甲双胍还是其他抗糖尿病药物,均不能降低患甲状腺癌的风险。(文章详见——BMC Cancer:神药二甲双胍可以降低甲状腺癌风险吗?

【5】二甲双胍的抗肿瘤作用

无论是在动物,还是人体试验,都发现二甲双胍可以通过AMPK依赖的通路抑制哺乳动物类雷帕霉素靶蛋白信号通路,抑制肿瘤细胞的生长。早期的观察性研究发现,在使用二甲双胍治疗的糖尿病患者中,癌症的发生风险降低,已存在癌症的进展被阻止。

多项研究表明,二甲双胍可以影响NF- kB的活性。NF- kB是一种转录因子,可以激活许多种癌症,调节与细胞增殖、存活、侵袭有关的多种基因。而CXCL8是NF- kB信号系统下游的,与甲状腺癌的生长和进展相关的一个关键的介导因子,在体动物甲状腺癌实验发现,以CXCL8为靶向的治疗可以延长生存期,减少肿瘤的转移。

在人甲状腺癌细胞的原代培养中,二甲双胍可以逆转TNF-a诱导的CXCL8的分泌,二甲双胍表现出间接的抗肿瘤效应。研究者使用TNF-a单独或/结合二甲双胍(0.01, 0.1, 1, 2.5, 5, and 10mM)浓度组,刺激正常甲状腺细胞,甲状腺乳头状癌细胞,及甲状腺癌细胞系(TPC-1和BCPAP),将细胞培养24小时后,检测细胞上清液中CXCL8的水平。结果显示:在正常甲状腺细胞(ANOVA: F=42.04; P<0 .0001)和乳头状甲状腺癌细胞(ANOVA: F = 21.691; P <0 .0001)中,二甲双胍显著的抑制TNF-a诱导的CXCL8的分泌,并呈现浓度依赖性,但是在TPC-1 和 BCPAP细胞系中并没有得出此结论。

因此,在原代培养的正常甲状腺癌细胞和已分化的甲状腺癌细胞中,至少是在最常见的侵袭性最差的甲状腺癌表型中,二甲双胍可以抑制TNF-a诱导的CXCL8的分泌。甲状腺组织中中性粒细胞的募集是非常关紧的促代谢因素,在暴露于TNF-a刺激中的肿瘤细胞和大多数正常甲状腺细胞中,它取决于细胞分泌的CXCL8的数量。固此研究发现的二甲双胍对TNF-a诱导的CXCL8分泌的抑制作用,可以认为是二甲双胍的一个间接的抗肿瘤效应。(文章详见——JCEM:二甲双胍的抗肿瘤作用

【6】二甲双胍可能还能降低糖尿病患者的肺癌风险

Sakoda和他的同事对47351名糖尿病患者(其中男性占54% )进行了一项回顾性队列研究。该群患者年龄为40岁或以上,均在1994年和1996年之间完成了健康相关信息调查。他们的糖尿病药物使用记录被药房的电子记录所收集。记录中在六个月期间使用两个或两个以上的二甲双胍处方的患者,被定义为二甲双胍“终身使用者”,约占总人数的46%。在15年的随访中,总共有747名患者被诊断出患有肺癌,其中80名为不吸烟者,而203名当时是吸烟者。

研究结果发现,二甲双胍的使用并不能降低整体糖尿病患者发生肺癌的风险。然而,对于从未吸烟的糖尿病患者,使用二甲双胍能够导致肺癌发生的风险比吸烟者低43%,并且持续使用似乎有利于进一步降低风险。不吸烟者使用二甲双胍五年或更长时间能够降低52%肺癌发病的风险,但是这个发现在统计学上并不显著。使用二甲双胍五年或以上与腺癌的发病风险降低31%相关,而腺癌则是非吸烟者最常见的一种肺癌诊断;同时提高了82%经常在吸烟者诊断的小细胞癌的风险,但这些研究结果并不具有统计学意义。(文章详见——Cancer Prev Res:二甲双胍可能还能降低糖尿病患者的肺癌风险

【7】二甲双胍能降低2型糖尿病患者前列腺癌风险

研究人员检索1998年~2002年台湾国民健康保险报销数据库中新发2型糖尿病且年龄>40岁(N=395481)的男性患者,对这些患者是否发生前列腺癌进行随访,直到2009年。将二甲双胍作为一个随时间变化的变量。所研究的病人中,有209269人从未使用二甲双胍,186212人一直使用二甲双胍。使用时间依赖性方式计算前列腺癌的发病率,应用Cox回归评估一直使用二甲双胍患者、从未使用二甲双胍患者、二甲双胍暴露亚组患者(累积持续时间和累积剂量的三分位数)的风险比。使用时间依赖性和非时间依赖性方法对各亚组进行敏感性分析。

在随访期间,2776名二甲双胍一直使用者及9642名二甲双胍从未使用者发展为前列腺癌,发生率分别为239.42/100000人年及737.10/100000人年。校正倾向得分(PS)后,二甲双胍一直使用者 vs 二甲双胍从未使用者的风险比(95%可信区间)为0.467 (0.446~0.488)。校正PS后,二甲双胍治疗累积持续时间的第一、第二、第三三分位数风险比分别为0.741 (0.698~0.786)、0.474 (0.441~0.508) 和0.231 (0.212~0.253) (P <0.001);二甲双胍治疗累积剂量的第一、第二、第三三分位数风险比分别为0.742 (0.700~0.786)、0.436 (0.406~0.468) 和0.228 (0.208~0.251) (P <0.001)。敏感性分析一致支持二甲双胍对前列腺癌的保护作用。

结果表明,使用二甲双胍可以降低台湾男性2型糖尿病患者偶发前列腺癌的风险。(文章详见——Eur J Cancer:二甲双胍能降低2型糖尿病患者前列腺癌风险

【8】研究发现二甲双胍抗癌的直接证据

来自麻省理工怀特黑德研究所(Whitehead, MIT)的科学家们确定了一条使得癌细胞能够在低葡萄糖环境中存活的重要线粒体信号通路。通过寻找这一信号通路发生缺陷或是葡萄糖利用受损的癌细胞,科学家们可以预测哪些肿瘤将会对已知抑制这一线粒体信号通路的抗糖尿病药物敏感。

为了研究癌细胞在癌性肿瘤低葡萄糖环境中生存的机制,研究所成员 David Sabatini 和他的同事们开发了一种环绕细胞不断循环低营养物培养基的系统。在这一系统内测试的 30% 的癌细胞系几乎都不受葡萄糖缺乏的影响。少数细胞系旺盛生长及快速增殖,而另一些则竭力挣扎。这些细胞系对于葡萄糖缺乏产生这样不同的反应令人费解。

研究人员试图了解是否能够利用某些癌细胞对于低葡萄糖环境敏感来攻击肿瘤。他们在极度困窘的细胞中筛查了受到抑制时提高或进一步阻碍细胞生存率的基因。筛查标记出了一些与葡萄糖运输和线粒体中氧化磷酸化代谢信号通路相关的基因。细胞的发电所——线粒体是一种带有自身 DNA 的膜结合细胞器,其中包含有控制氧化磷酸化的基因。

研究人员推测,这些基因发生突变的癌细胞在正常条件下使得它们的线粒体超负荷。当置于严苛的低葡萄糖环境时,线粒体竭尽全力,细胞受损。如果情况确是如此,这一假设表明已知作为氧化磷酸化抑制剂的双胍类,有可能通过将线粒体推至极限,进一步损害线粒体功能,损伤了癌细胞。

他们首先在体外对13种葡萄糖利用缺陷及线粒体 DNA 突变的细胞系进行了假设测试。相比于对照细胞,这些对低葡萄糖敏感5-20倍的细胞对于苯乙双胍(一种比二甲双胍更有效的双胍类药物)更为敏感。研究人员随后在移植低葡萄糖敏感癌细胞衍生肿瘤的小鼠中检测了苯乙双胍的效应。这一药物抑制了肿瘤生长。

这些结果表明,可以利用线粒体 DNA 突变和葡萄糖输入缺陷作为双胍类敏感性的生物标记物,确定一名癌症患者是否有可能从这些药物中获益。这是第一次有人证实,包括二甲双胍和苯乙双胍在内的这类药物通过影响线粒体对癌细胞发挥直接细胞毒性效应。(文章详见——Nature:研究发现二甲双胍抗癌的直接证据

【9】二甲双胍可抑制分化型甲状腺癌生长

来自美国国防医科大学的Vasyl Vasko教授及其团队进行了一项研究,该研究中,比较使用二甲双胍治疗的糖尿病患者(MF+组,34例)与未使用二甲双胍治疗的糖尿病患者(MF-组,21例)、以及非糖尿病患者组(C组,185例)之间的完全缓解率。同时在体外检验二甲双胍对DTC细胞的影响。

该研究结果表明,三组间在年龄、性别、体重指数(BMI)、糖尿病管理、多病灶肿瘤生长的频率、甲状腺外扩散、局部和远处转移方面具有可比性。MF+组与MF-组和C组相比,肿瘤大小显著缩小(1.37±0.97cm vs 2.44±1.49cm vs 2.39±1.73cm,P=0.026)。多变量模型显示甲状腺外扩散(P=0.018)、远处转移(P<0.0001)、以及糖尿病缺乏二甲双胍治疗(p P<0.0001)降低CR的可能性。COX风险模型显示年龄(P=0.025)、局部转移(P=0.022)、远处转移(P=0.003)和糖尿病缺乏二甲双胍治疗(P=0.014)与无进展生存期(PFS)缩短风险增加有关。体外数据显示二甲双胍抑制癌细胞生长,激活CAMP诱导蛋白激酶(AMPK)和下调p70S6K/pS6。二甲双胍加强H2O2诱导的AMPK激活,但减弱pERK和p70S6K。MF+患者的肿瘤与MF-组相比,显示低水平磷酸化p70S6K。

该研究发现,在肿瘤比较小的患者使用二甲双胍治疗,提示通过二甲双胍可抑制肿瘤生长。在糖尿病患者中,缺少二甲双胍治疗是完全缓解(CR)可能性减少和无进展生存期缩短风险增加的独立因素。体外数据提示在DTC细胞中,p70S6K/PS6可能是二甲双胍的分子靶位。(文章详见——JCEM:二甲双胍可抑制分化型甲状腺癌生长

【10】二甲双胍或降低糖尿病患者结直肠癌风险

Singh医生及其同事对15项评估降糖药物与CRC风险关联的研究进行了系统综述和Meta分析。各项研究之间存在明显异质性。具体包括5项病例对照研究、8项队列研究和2项随机对照试验,共涉及841,000例糖尿病患者中发生的近14,000例CRC。

分析结果显示,接受二甲双胍治疗者的CRC发病率降低了10%[10项研究;校正比值比(AOR),0.90;95%置信区间(CI),0.82~0.99;P=0.02]。即使仅分析高质量的观察性研究(7项研究;AOR,0.88;95%CI,0.79~0.98),仍然得出一致的结果。使用磺酰脲类(8项研究;AOR,1.12;95%CI,0.99~1.26;P=0.07)或胰岛素(10项研究;AOR,1.25;95%CI,0.91~1.71;P=0.17)的患者具有较高的CRC风险,不过均不具有统计学意义。TZD与CRC风险无关(6项研究;AOR,0.95;95%CI,0.87~1.03;P=0.24)。

Singh医生认为,值得开展前瞻性队列研究或随机对照试验来评估二甲双胍对于成年2型糖尿病患者的化学预防效应。(文章详见——DDW 2013:二甲双胍或降低糖尿病患者结直肠癌风险

【11】研究证实二甲双胍具有抗肿瘤作用

研究小组查看了341名I~IV期卵巢上皮癌(n=273)、输卵管癌(n=34)和腹膜癌(n=34)患者的数据,时间是1992~2010年。队列中包含16名使用二甲双胍的糖尿病患者,28名没有使用。

不管是否患有糖尿病,这些妇女接受相同的方法治疗卵巢癌。各组间手术后小于1cm的残余肿瘤行细胞减灭术比例,使用的化疗类型,化疗周期相似。几乎所有的妇女(95%)都接受基于铂类和紫衫类为基础的化疗,最常用的是卡铂和紫杉醇。

该研究报告认为,使用二甲双胍的糖尿病患者5年无进展生存率为51%,没使用二甲双胍的糖尿病病人为8%,非糖尿病患者为23%(p=0.03)。使用二甲双胍的5年总体存活率为63%,未使用二甲双胍的是23%,非糖尿病组为37%(p=0.03)。控制了“标准临床病理参数”后,二甲双胍的使用与无进展生存率显著相关,但是和总体生存率无相关性。

调整了混杂因素后的生存分析中,比较使用vs未使用二甲双胍的糖尿病患者,前者的疾病复发风险显著降低(HR,0.38)。二甲双胍组死亡风险也降低(HR,0.43),但差异未达到统计学差异。与非糖尿病组相比,使用二甲双胍组的疾病复发和死亡率也降低,但是无统计学差异。没有使用二甲双胍的糖尿病患者相比无糖尿病患者,癌症复发风险(HR,1.42)和死于疾病的风险(HR,1.33)要升高。

研究者注意到,其他研究也表明二甲双胍在多种癌症中都具有抗肿瘤作用,包括乳腺癌、前列腺癌、结肠癌和卵巢癌。临床和实验室研究也表明,二甲双胍可以提高病人对化疗的反应。目前的研究来看,二甲双胍使用者对化疗的反应最好。(文章详见——Obstet Gynecol :研究证实二甲双胍具有抗肿瘤作用

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (24)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=146842, encodeId=6bed14684214, content=二甲双胍主要还是降糖药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Oct 12 13:56:32 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139483, encodeId=d268139483df, content=很好非常有帮助,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Mon Oct 03 11:34:38 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138722, encodeId=4c68138e2220, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:36 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138721, encodeId=6728138e21da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138662, encodeId=6a321386628a, content=可能是一厢情愿的事情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Oct 01 17:27:57 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=134389, encodeId=7f95134389da, content=主要还是用于降糖。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 24 17:38:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133441, encodeId=08b3133441cf, content=“减肥药”, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133439, encodeId=a7b613343933, content=厉害,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133440, encodeId=fd60133440f0, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133357, encodeId=aea613335e77, content=刚刚知道,二甲双胍有这么多的治疗作用,值得学习啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1104997918/231D86F03CD9EE07FB0C75BDC037C1E0/100, createdBy=2aa71721540, createdName=QQe072d2fb, createdTime=Fri Sep 23 10:14:00 CST 2016, time=2016-09-23, status=1, ipAttribution=)]
    2016-10-12 jyzxjiangqin

    二甲双胍主要还是降糖药物。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=146842, encodeId=6bed14684214, content=二甲双胍主要还是降糖药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Oct 12 13:56:32 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139483, encodeId=d268139483df, content=很好非常有帮助,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Mon Oct 03 11:34:38 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138722, encodeId=4c68138e2220, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:36 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138721, encodeId=6728138e21da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138662, encodeId=6a321386628a, content=可能是一厢情愿的事情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Oct 01 17:27:57 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=134389, encodeId=7f95134389da, content=主要还是用于降糖。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 24 17:38:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133441, encodeId=08b3133441cf, content=“减肥药”, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133439, encodeId=a7b613343933, content=厉害,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133440, encodeId=fd60133440f0, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133357, encodeId=aea613335e77, content=刚刚知道,二甲双胍有这么多的治疗作用,值得学习啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1104997918/231D86F03CD9EE07FB0C75BDC037C1E0/100, createdBy=2aa71721540, createdName=QQe072d2fb, createdTime=Fri Sep 23 10:14:00 CST 2016, time=2016-09-23, status=1, ipAttribution=)]
    2016-10-03 右脚梅西

    很好非常有帮助,谢谢。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=146842, encodeId=6bed14684214, content=二甲双胍主要还是降糖药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Oct 12 13:56:32 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139483, encodeId=d268139483df, content=很好非常有帮助,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Mon Oct 03 11:34:38 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138722, encodeId=4c68138e2220, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:36 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138721, encodeId=6728138e21da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138662, encodeId=6a321386628a, content=可能是一厢情愿的事情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Oct 01 17:27:57 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=134389, encodeId=7f95134389da, content=主要还是用于降糖。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 24 17:38:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133441, encodeId=08b3133441cf, content=“减肥药”, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133439, encodeId=a7b613343933, content=厉害,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133440, encodeId=fd60133440f0, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133357, encodeId=aea613335e77, content=刚刚知道,二甲双胍有这么多的治疗作用,值得学习啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1104997918/231D86F03CD9EE07FB0C75BDC037C1E0/100, createdBy=2aa71721540, createdName=QQe072d2fb, createdTime=Fri Sep 23 10:14:00 CST 2016, time=2016-09-23, status=1, ipAttribution=)]
    2016-10-01 doctorJiangchao

    继续关注

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=146842, encodeId=6bed14684214, content=二甲双胍主要还是降糖药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Oct 12 13:56:32 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139483, encodeId=d268139483df, content=很好非常有帮助,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Mon Oct 03 11:34:38 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138722, encodeId=4c68138e2220, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:36 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138721, encodeId=6728138e21da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138662, encodeId=6a321386628a, content=可能是一厢情愿的事情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Oct 01 17:27:57 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=134389, encodeId=7f95134389da, content=主要还是用于降糖。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 24 17:38:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133441, encodeId=08b3133441cf, content=“减肥药”, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133439, encodeId=a7b613343933, content=厉害,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133440, encodeId=fd60133440f0, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133357, encodeId=aea613335e77, content=刚刚知道,二甲双胍有这么多的治疗作用,值得学习啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1104997918/231D86F03CD9EE07FB0C75BDC037C1E0/100, createdBy=2aa71721540, createdName=QQe072d2fb, createdTime=Fri Sep 23 10:14:00 CST 2016, time=2016-09-23, status=1, ipAttribution=)]
    2016-10-01 doctorJiangchao

    继续学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=146842, encodeId=6bed14684214, content=二甲双胍主要还是降糖药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Oct 12 13:56:32 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139483, encodeId=d268139483df, content=很好非常有帮助,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Mon Oct 03 11:34:38 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138722, encodeId=4c68138e2220, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:36 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138721, encodeId=6728138e21da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138662, encodeId=6a321386628a, content=可能是一厢情愿的事情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Oct 01 17:27:57 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=134389, encodeId=7f95134389da, content=主要还是用于降糖。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 24 17:38:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133441, encodeId=08b3133441cf, content=“减肥药”, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133439, encodeId=a7b613343933, content=厉害,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133440, encodeId=fd60133440f0, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133357, encodeId=aea613335e77, content=刚刚知道,二甲双胍有这么多的治疗作用,值得学习啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1104997918/231D86F03CD9EE07FB0C75BDC037C1E0/100, createdBy=2aa71721540, createdName=QQe072d2fb, createdTime=Fri Sep 23 10:14:00 CST 2016, time=2016-09-23, status=1, ipAttribution=)]
    2016-10-01 jyzxjiangqin

    可能是一厢情愿的事情。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=146842, encodeId=6bed14684214, content=二甲双胍主要还是降糖药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Oct 12 13:56:32 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139483, encodeId=d268139483df, content=很好非常有帮助,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Mon Oct 03 11:34:38 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138722, encodeId=4c68138e2220, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:36 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138721, encodeId=6728138e21da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138662, encodeId=6a321386628a, content=可能是一厢情愿的事情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Oct 01 17:27:57 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=134389, encodeId=7f95134389da, content=主要还是用于降糖。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 24 17:38:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133441, encodeId=08b3133441cf, content=“减肥药”, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133439, encodeId=a7b613343933, content=厉害,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133440, encodeId=fd60133440f0, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133357, encodeId=aea613335e77, content=刚刚知道,二甲双胍有这么多的治疗作用,值得学习啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1104997918/231D86F03CD9EE07FB0C75BDC037C1E0/100, createdBy=2aa71721540, createdName=QQe072d2fb, createdTime=Fri Sep 23 10:14:00 CST 2016, time=2016-09-23, status=1, ipAttribution=)]
    2016-09-24 jyzxjiangqin

    主要还是用于降糖。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=146842, encodeId=6bed14684214, content=二甲双胍主要还是降糖药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Oct 12 13:56:32 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139483, encodeId=d268139483df, content=很好非常有帮助,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Mon Oct 03 11:34:38 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138722, encodeId=4c68138e2220, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:36 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138721, encodeId=6728138e21da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138662, encodeId=6a321386628a, content=可能是一厢情愿的事情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Oct 01 17:27:57 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=134389, encodeId=7f95134389da, content=主要还是用于降糖。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 24 17:38:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133441, encodeId=08b3133441cf, content=“减肥药”, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133439, encodeId=a7b613343933, content=厉害,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133440, encodeId=fd60133440f0, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133357, encodeId=aea613335e77, content=刚刚知道,二甲双胍有这么多的治疗作用,值得学习啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1104997918/231D86F03CD9EE07FB0C75BDC037C1E0/100, createdBy=2aa71721540, createdName=QQe072d2fb, createdTime=Fri Sep 23 10:14:00 CST 2016, time=2016-09-23, status=1, ipAttribution=)]
    2016-09-23 187清风

    “减肥药”

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=146842, encodeId=6bed14684214, content=二甲双胍主要还是降糖药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Oct 12 13:56:32 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139483, encodeId=d268139483df, content=很好非常有帮助,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Mon Oct 03 11:34:38 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138722, encodeId=4c68138e2220, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:36 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138721, encodeId=6728138e21da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138662, encodeId=6a321386628a, content=可能是一厢情愿的事情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Oct 01 17:27:57 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=134389, encodeId=7f95134389da, content=主要还是用于降糖。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 24 17:38:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133441, encodeId=08b3133441cf, content=“减肥药”, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133439, encodeId=a7b613343933, content=厉害,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133440, encodeId=fd60133440f0, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133357, encodeId=aea613335e77, content=刚刚知道,二甲双胍有这么多的治疗作用,值得学习啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1104997918/231D86F03CD9EE07FB0C75BDC037C1E0/100, createdBy=2aa71721540, createdName=QQe072d2fb, createdTime=Fri Sep 23 10:14:00 CST 2016, time=2016-09-23, status=1, ipAttribution=)]
    2016-09-23 187清风

    厉害,学习了

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=146842, encodeId=6bed14684214, content=二甲双胍主要还是降糖药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Oct 12 13:56:32 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139483, encodeId=d268139483df, content=很好非常有帮助,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Mon Oct 03 11:34:38 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138722, encodeId=4c68138e2220, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:36 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138721, encodeId=6728138e21da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138662, encodeId=6a321386628a, content=可能是一厢情愿的事情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Oct 01 17:27:57 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=134389, encodeId=7f95134389da, content=主要还是用于降糖。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 24 17:38:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133441, encodeId=08b3133441cf, content=“减肥药”, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133439, encodeId=a7b613343933, content=厉害,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133440, encodeId=fd60133440f0, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133357, encodeId=aea613335e77, content=刚刚知道,二甲双胍有这么多的治疗作用,值得学习啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1104997918/231D86F03CD9EE07FB0C75BDC037C1E0/100, createdBy=2aa71721540, createdName=QQe072d2fb, createdTime=Fri Sep 23 10:14:00 CST 2016, time=2016-09-23, status=1, ipAttribution=)]
    2016-09-23 187清风

    继续学习

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=146842, encodeId=6bed14684214, content=二甲双胍主要还是降糖药物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Oct 12 13:56:32 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139483, encodeId=d268139483df, content=很好非常有帮助,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Mon Oct 03 11:34:38 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138722, encodeId=4c68138e2220, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:36 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138721, encodeId=6728138e21da, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Oct 01 21:30:31 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138662, encodeId=6a321386628a, content=可能是一厢情愿的事情。, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Oct 01 17:27:57 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=134389, encodeId=7f95134389da, content=主要还是用于降糖。, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Sep 24 17:38:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133441, encodeId=08b3133441cf, content=“减肥药”, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133439, encodeId=a7b613343933, content=厉害,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133440, encodeId=fd60133440f0, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Fri Sep 23 13:15:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133357, encodeId=aea613335e77, content=刚刚知道,二甲双胍有这么多的治疗作用,值得学习啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1104997918/231D86F03CD9EE07FB0C75BDC037C1E0/100, createdBy=2aa71721540, createdName=QQe072d2fb, createdTime=Fri Sep 23 10:14:00 CST 2016, time=2016-09-23, status=1, ipAttribution=)]
    2016-09-23 QQe072d2fb

    刚刚知道,二甲双胍有这么多的治疗作用,值得学习啊

    0

相关资讯

Diabetes Care:HIV感染 vs 非感染,口服降糖药的有效性研究

目的:2型糖尿病在艾滋病病毒感染者中越来越常见。本研究的目的旨在比较不同HIV感染状态患者的口服降糖药对血糖控制的有效性(HIV感染者 vs 非HIV感染者)。 方法:该纵向队列研究纳入了HIV感染或非感染的2型糖尿病退伍军人,在1999-2010年间开始使用糖尿病药物。校正基线糖化血红蛋白水平与临床变量后,使用广义估计方程,比较治疗一年后的糖化血红蛋白(HbA1c)变化。 结果:在研

Diabetes Care:DKA+严重高血糖,血糖恢复正常后,该选用什么药物呢?

背景:许多新发糖尿病酮症酸中毒(DKA)+严重高血糖+肥胖的非洲裔美国患者,经过胰岛素强化治疗后,能够达到接近正常血糖的缓解。但是缓解后,预防高血糖复发的最佳治疗又是什么呢? 方法:这项为期4年的前瞻性、安慰剂对照研究,纳入了48名DKA+严重高血糖的非洲裔美国患者,血糖缓解后,随机分为二甲双胍(每日 1000mg;n = 17)、西他列汀(每日 100mg;n = 16)或安慰剂组(n =

Diabetes Care:5-HTTLPR基因多态性与二甲双胍胃肠道不耐受

目的:服用二甲双胍时,为啥会出现胃肠道不耐受?先前的研究表明,有机阳离子转运蛋白1(OCT1)功能降低等位基因与二甲双胍不耐受性的增加有关。考虑到最近的研究发现,5-羟色胺转运体(SERT)可能也参与了二甲双胍肠吸收这个过程,以及胃肠道生理中5-羟色胺的作用,本研究调查了SERT基因的常见多态性和二甲双胍胃肠道不耐受之间的联系。 方法:研究纳入了1365例完全耐受二甲双胍和164例极度不耐受

二甲双胍真能抗肿瘤吗?看这里!

二甲双胍是目前治疗2型糖尿病的一线用药,而近年来,国内外众多研究显示,二甲双胍不仅具有降血糖的作用,还具有抗肿瘤的作用。那么,二甲双胍对抗肿瘤是通过哪些作用机制产生的呢?9月2日在第17届国际内分泌大会暨第十五次全国内分泌学学术会议上,来自上海交通大学附属第一人民医院的彭永德教授作了题为“二甲双胍抗肿瘤作用机制探讨”的报告,从“糖尿病与肿瘤”、“二甲双胍对肿瘤的影响”、“二甲双胍抗肿瘤的作用机制”

Diabetes Care:依帕列净+二甲双胍联合治疗2型糖尿病

目的:本研究对象为2型糖尿病患者,比较依帕列净+二甲双胍联合治疗 vs 依帕列净或二甲双胍单药治疗的疗效和安全性。 方法:研究纳入了1364例没有使用药物治疗过的2型糖尿病患者(HbA1c >7.5~≤12% [>58 to ≤108 mmol/mol]),进行长达24周的研究。治疗方式有:依帕列净 12.5 mg 每天两次+二甲双胍 1000 mg 每天两次;依帕列净 12

扒一扒“包治百病”的二甲双胍

导语:近些年,多项研究表明二甲双胍具有减重、延缓衰老、抗癌等作用。但是万物皆有两面性,即使是神药也不是十全十美的。二甲双胍自1957年问世以来,已经在国际上使用了近60年,在我国也已有近20年的使用经验。二甲双胍在各种2型糖尿病防治指南中,都处在一线用药的王牌地位。但二甲双胍的“野心”还不止于此——近年来,大量研究发现,二甲双胍还有抗衰老、抗癌等“特异功能”。今天我们就先来“肢解”二甲双胍的“